CA1258642A - Hollow fiber plasmapheresis module and process - Google Patents

Hollow fiber plasmapheresis module and process

Info

Publication number
CA1258642A
CA1258642A CA000443383A CA443383A CA1258642A CA 1258642 A CA1258642 A CA 1258642A CA 000443383 A CA000443383 A CA 000443383A CA 443383 A CA443383 A CA 443383A CA 1258642 A CA1258642 A CA 1258642A
Authority
CA
Canada
Prior art keywords
blood
fibers
plasma
module
ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000443383A
Other languages
French (fr)
Inventor
Ray B. Duggins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EIDP Inc
Original Assignee
EI Du Pont de Nemours and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EI Du Pont de Nemours and Co filed Critical EI Du Pont de Nemours and Co
Application granted granted Critical
Publication of CA1258642A publication Critical patent/CA1258642A/en
Expired legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D63/00Apparatus in general for separation processes using semi-permeable membranes
    • B01D63/02Hollow fibre modules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3403Regulation parameters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3496Plasmapheresis; Leucopheresis; Lymphopheresis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3601Extra-corporeal circuits in which the blood fluid passes more than once through the treatment unit
    • A61M1/3603Extra-corporeal circuits in which the blood fluid passes more than once through the treatment unit in the same direction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3601Extra-corporeal circuits in which the blood fluid passes more than once through the treatment unit
    • A61M1/3604Extra-corporeal circuits in which the blood fluid passes more than once through the treatment unit in opposite directions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M60/00Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance
    • A61M60/10Location thereof with respect to the patient's body
    • A61M60/104Extracorporeal pumps, i.e. the blood being pumped outside the patient's body
    • A61M60/109Extracorporeal pumps, i.e. the blood being pumped outside the patient's body incorporated within extracorporeal blood circuits or systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M60/00Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance
    • A61M60/20Type thereof
    • A61M60/247Positive displacement blood pumps
    • A61M60/253Positive displacement blood pumps including a displacement member directly acting on the blood
    • A61M60/268Positive displacement blood pumps including a displacement member directly acting on the blood the displacement member being flexible, e.g. membranes, diaphragms or bladders
    • A61M60/279Peristaltic pumps, e.g. roller pumps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M60/00Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance
    • A61M60/30Medical purposes thereof other than the enhancement of the cardiac output
    • A61M60/36Medical purposes thereof other than the enhancement of the cardiac output for specific blood treatment; for specific therapy
    • A61M60/37Haemodialysis, haemofiltration or diafiltration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M60/00Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance
    • A61M60/40Details relating to driving
    • A61M60/424Details relating to driving for positive displacement blood pumps
    • A61M60/438Details relating to driving for positive displacement blood pumps the force acting on the blood contacting member being mechanical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M60/00Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance
    • A61M60/80Constructional details other than related to driving
    • A61M60/845Constructional details other than related to driving of extracorporeal blood pumps
    • A61M60/851Valves
    • A61M60/853Valves the valve being formed by a flexible tube element which is clamped for restricting the flow
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D61/00Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14Ultrafiltration; Microfiltration
    • B01D61/147Microfiltration
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D65/00Accessories or auxiliary operations, in general, for separation processes or apparatus using semi-permeable membranes
    • B01D65/08Prevention of membrane fouling or of concentration polarisation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621Extra-corporeal blood circuits
    • A61M1/3623Means for actively controlling temperature of blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/33Controlling, regulating or measuring
    • A61M2205/3306Optical measuring means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/33Controlling, regulating or measuring
    • A61M2205/3331Pressure; Flow
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/33Controlling, regulating or measuring
    • A61M2205/3331Pressure; Flow
    • A61M2205/3334Measuring or controlling the flow rate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M60/00Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance
    • A61M60/10Location thereof with respect to the patient's body
    • A61M60/104Extracorporeal pumps, i.e. the blood being pumped outside the patient's body
    • A61M60/109Extracorporeal pumps, i.e. the blood being pumped outside the patient's body incorporated within extracorporeal blood circuits or systems
    • A61M60/113Extracorporeal pumps, i.e. the blood being pumped outside the patient's body incorporated within extracorporeal blood circuits or systems in other functional devices, e.g. dialysers or heart-lung machines
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2321/00Details relating to membrane cleaning, regeneration, sterilization or to the prevention of fouling
    • B01D2321/20By influencing the flow
    • B01D2321/2066Pulsated flow
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2321/00Details relating to membrane cleaning, regeneration, sterilization or to the prevention of fouling
    • B01D2321/20By influencing the flow
    • B01D2321/2083By reversing the flow

Abstract

TITLE

Hollow Fiber Plasmapheresis Module and Process ABSTRACT OF THE DISCLOSURE
Hollow fiber plasmapheresis module and process, said module comprising hollow fibers having cell-retaining pores and an effective length (L) to lumen diameter (D) ratio L/D not greater than 16,400 cm-1 D
(L and D being in centimeters) within a housing having a blood inlet for conducting blood to the fibers, an outlet for conducting exit (plasma-depleted) blood from the fibers, and a plasma outlet for conducting plasma out of the module.

Description

TITLE
Hollow Fiber Plasmapheresis ~odule and Process TECHNICAL FIELD
This inven~ion relates to plasmapheresis 5 using microporous hollow fibers~
BACKGROUND INFOXMATION
Plasmapheresi~ is a process of separating plasma from whole blood. The plasma-depleted blood is comprised principally of cellular components, e.g., 10 red blood cells, white blood cells and platelets.
Plasma is comprised largely of water, but also con-tains proteins and various other non-cellular compounds, bo~h organic and inorganic.
Plasmapheresis is currently used ~o ob~ain 15 plasma for various transfusion needs, e.g., prepara-tion of fresh-frozen plasma for subsequent fractiona~
tion to obtain specific proteins such as serum albumin, to produce cell culture media, and for disease therapies involving either the replacement of plasma 20 or removal of speci~ic disease contributing factors from the plasma.

.

~ .
2 ~ j L~ ~
Plasmapheresis can he carried out by centri-fugation or microfiltration. Microfiltration apparatus generally utilize microporous membranes. The pores are cell-retaining pores, that is, the pores sub-5 stantially re~ain cellular components but allow plasmato pass through. Typically, ceLl-retaining pores are of substantially uniform diameter and are of a size with-in the range 0.1 to 1.0 micrometer, that is, between membranes the Iore size is within this range, but in any single membrane the pores are of substantially the same size.
Various planar membrane devices are disclosed in the literature. These include various configurations ~ of membranes and flow-paths. In general, microporous hollow fibers are being increasingly used. Gurland et al., in a paper presented at the 1981 annual mesting of the American Society for Artificial Internal Organs, reported that three hollow iber plasma-pheresis modules were comm~rcially available. These are the Plasmaflo 01, Plasmaflo 02 and Plasmaflux, the first two utilizing cellulose diacetate membranes with a maximum pore size of 0.2 ~m, and the third, utilizing polypropylene with a maximum pore size of 0.5 ~m. Other features are listed below.

Effective E~fective WaLl Lumen lengthsurface ~hickness Module(~m) (cm) (M2) (~m) ... . . . ~
PLasma flo 01 370 about 20 0.65 160 PLasma-- flo 02330 about 20 0.5 6~ :-Plasma-- flux 330 about 20 0.5 140 ---~
. 2 "Continuous plasmapheresi~", as the term is used herein, is ~he process of continuously separating plasma from whole blood. Thus, as the term is used herein, "continuous plasmapheresis", and the apparatus S needed to carry out a continuous plasmapheresis, must be able to provide, from whole blood, sufficient plasma, for example, at least about 500 mL, in a relatively short time, for example, lS minutes to 3 hours, with-out substantial fouling of the membrane pores~ The la whole blood used in this invention either oan be pro-vided directly by a donor or patient or it can first be collected from a donor or patient and subsequently introduced into the apparatus of this invention, for example,from a reservoir.

15 It is an object of this invention to provide a hollow fiber plasmapheresis module which provides a high rate of plasma collection per unit area of membrane and which thus requires a small extracorporeal blood volume and a small surface area of membrane material, 20 considered a foxeign material to the blood. Another object is to provide such a module which not only pro-vides a high plasma flux but also a high hematocrit in the plasma-depleted fraction. A further object is to provide a module which can operate ~ontinuously for 2S longer periods of time than conventional plasmapheresis modules, thus making it suitable for use in continuous plasmapheresi A~other object is to provide such a -module which is ~asy to assemble and easy to use without- - -. - making extensi~e adjus~ments. A further objéct i~-t* -::

provide a plasmapheresis process employing hollow fiber membranes. Other objects will become apparent hereinafter.
BRIEF DESCRIPTIO~I OF THE DRAWINGS
Figure 1 i5 a flow diagram which shows the hollow fiber module of the invention as it may be used with attendant communicating apparatus in carrying out a continuous plasmapheresis in either the steady state/recycle or pulsed flow mode of the invention.
10 Figure 2 is an enlarged view o a part of Figuxe l to show the direction of blood flow in the recycle mode of the invention. Figure 3 shows the direction of blood flow on the forward stroke o the pul~er pump in the pulsed flow mode of the invention, and Figure 4 shows the direction of blood flow on the reverse stroke in this mode of operation. Figure 5 shows the variation of ~ransmembrane pressure difference with varia~ion of membrane pore size; ~hus a higher trans-membrane pressure difference can ~e tolerated as the pore size is decreased.
SUMMARY OF THE INVENTION
In my earlier applications, supra, are dis-closed and ciaimed process and apparatus for carrying out plasmapheresis using reciprocatory pulsatile blood 2~ flow across a porous membrane, such as a 1at membrane or hollow fibers. Tha instant invention involves the use o~ hvllow ~ibers but, unlike the earlier invention, ~ 5~6~
the flow of blood across the membrane can be either of the reciprocatory pulsatile type or of ~he steady state type. The steady state type invention also includes a variation wherein a recycle blood flow is employed.
5 Figure 1 depicts an apparatus for carrying out either the steady state/recycle or pulsed flow mode of the inventioIl. Such an apparatus without the let pump and recycle loop can be used on carry out the steady state mode of ~he invention.
The invention herein resides in a hollow fiber plasmapheresis module comprising hollow fibers having cell-retaining pores and an effective length substantially less than tha~ commonly used in th~ art~
within a housing having a blood inlet for conducting 15 blood to the fibers, an outlet for conducting exit (plasma-depleted) blood ~rom the fibers, and a plasma outlet for conducting plasma out of the moduleO The invention also resides in a process for using the afore-said module for carrying out a plasmapheresis, especially 20 on a continuou.s basis on a human subject. The immedi-ately-following discussion i5 directed to the mechanics of steady state, recycle and reciprocatory ~ulsatile ~low (pulsed flow) embodiments of the in~ention. Vari-ables with each ~low mode and their relationship to 25 module p~rformance are also di~cussed.
STEADY STATh' FLOW PLASMAPHERESIS
The mo~t desirable microporous hollow fiber 6 ~s~
plasmapheresis device removPs the largest amount of plasma in the least amount of time, given the limited blood flow rate a~ailable from the patient. In this type of unit operating in the steady state flow mode, 5 whole blood is pumped to one end of the fibers. As theblood flows through the fibers some of the plasma escapes through the pores, leaving blood a~ the outlet with a slightly elevated hematocrit. An adjustable clamp, valve or pump can be placed on the blood outlQt 10 line to maintain the desired level of pressure within the module.
A problem with steady state flow is the interrelationship of outlet hematocrit and the quan~ity of plasma produced. Time is necessary for the plasma to 15 be forced out through the pores. Faster blood flow rates allow more plasma to be produced, but a larger volume of whole blood is needed. The net result is that the hematocrit i6 lower than is obtained with slower blood flow rates. The optimum operating con-20 ditions thus depend on the goals set for the particularmodule. High hematocrit goals dictate a lower optimum blood flow rate, whereas peak plasma production re-quires faster blood flow rates. Under steady state flow conditions the best mode represents a compxomise 25 of th~se parameters.

. . , A ~ariation of the steady state mode is the recycle flow mode wherein ~he flow of whole blood is augmented with some of the higher hematocrit blood 5 that exits the fibers. A tuhing loop and a pump are added to the device to recycle the highex hematocrit blood. This is shown in Figures 1 and 2. Figure 2 depicts the 10w of blood in the tubing loop as going in a direction from the region of the module outlet 10 to the region of the module inlet. It is to be under-stood that the recycle pump can also be installed so that the flow of blood in the t~bing loop goes in the reverse direction. In the recycle mode~ the velocity of blood flowing through the module is increased, which 15 in turn enhances plasma production. This result is achieved without increasing the flow rate of the blood, for example, from the patient. The hematocrik of the in-coming blood thus is increased befQre it enters the fibers due to the mixing of the inlet blood supply and "~ the blood in the recycle loop which has already been filtered. By utilizing the recycle flow mode a higher hematocrit and increased plasma production, as compared to steady state flow, can be realized. However, under this mode of operation the hematocrit and plasma pro 25 duction decrease with increasing time of operation.
T~e cause of this deteriora~ion of results is related ~ 5 ~

to blockage of ~he membrane pores by the blood cells, as will be described below.
It is generally recogniæed in the art that the rate of plasma flow ~hrough ~he pores of the fib r 5 (flux density) is usually not dependent on the trans-membrane pressure (TMP) as long as the TMP is within certain limits (the "plateau region"). ~elow about 50 mm of Hg pressure plasma flow rises sharply with increasing pressure, as it does above about 175 mm of 10 Hg pressure; above about 175 mm of Hg, however, thare is grave risk of hemolysis. For a recycle flow plasma-pher~sis unit to be economically and medically acceptable, it should be operat~d in this "plateau region".
Classical fluid mechanics equations can be 15 written to demons.trate that the transmembrane pressure ~aries along the length of the fiber. Xnitially, plasma production is greatest in the area of the fiber membrane near the whole blood inlet (the upper e~d of the fibers) where the transmembrane pressure is in the 20 plateau region. This pressure drops along the length of the fiber, falling to 0 mm of Hg, and then below 0 (with packed cell pumt~ing), near the outlet (the lower end of the fibers) for the plasma-depleted blood (also referred to herein as "packed cells", "filtered 25 blood" dA~ ~celLulax-enriched bloodnl. This negative ~P
draws some of the plasma that was forced through the pores along the upper end of the fibers back through the pores along ~he lower end o~ the fibers, resul~ing in a decrease in net plasma production. Thus, the long term perfo~m-ance of a plasmapheresis uni~ operated in the recycle flow mode can be subject to the adverse effects of 5 negative TMP.
In addition, the long term~performance of the recycle mode is deficient due to another factor. As the module operation continues, some cellular components of the blood are drawn to the fiber pores with the 10 plasma flow and block the pores, pre~enting further plasma flow through the pores. This pore blockage be-gins in the region of the fiber that experiences the highest transmembrane pressure, generally the region closest to the whole blood inlet. As the pores in this lS region become blocked, plasma flows through the next available open pores, in which event additional pore blockage takes place. Pore blockage continues down the fiber until all the pores are bl~cked~
Pore blockage may be diminished, either by 20 decreasing the inlet blood flow or by decreasing the transmembrane pressure. Either method undesirably re duces the plasma output and increases the time neces-sary for carrying out the plasmapheresis.
RECIPROCATORY PULSATILE FLOW
In this mode, also referred to as pulsed flow~
the advantage of recycle flow, that is, increased blood ~ 3L~
velocity through the fibers, is retain d, while the problem of cellular deposition in the pores is dimin-ished.
To operate in the pulse~ flow mode, a tubing 5 loop is included in the plasmapheresis unit to connec~ the two ends of th~ module, as shown in Figure 1. This loop includes a pulser pump which periodically reverses dlrection at a preselected frequency. The pump alter-nately draws blood from the exit (efferent) end of 10 the unit and pumps it into the whole blood inlet (afferent3 end o the unit on a forward stro;ce (Figure 3), then reverses direction and draws blood from the afferent end of the module and pumps it into the efferent end on a reverse stroke (Fiaure 4).
15 Alon~ with the frequency, the length and/or velocity of each stroke can be set, these variables being useful in controlling the volume of blood passing through the loop. ~he volum~ of blood passing through the loop on the forward and reverse strokes need not be the same, 20 and preferably are not the same. The volume of blood being pulsed in the system on the eikher stroke is at least 5%, pre~erably at least 10~, of the total volume of blood in the system.
On the ~orward stroke when the inlet whole 25 blood and the filtered (higher hematocrit) blood meet at the afferent end of the module, they are for~

36~
through the fib~rs under an increased pressure. At the efferent end oE th~ module the ~lood is under less pres-sure and, in fact, this decreased pressure may, for example, as described hereinafter for a preferred embodi-5 ment, result in a partial vacuum.
When the direction of the pulser pump is re-versed, blood from the blood supply and from the module flows to the pulser loop and a partial vacuum may re-sult at the afferent end of the module. Vacuum for-mation can be controlled by proper adjustment of a backpressure valve on the filtered blood outlet line. This valve, properly adjusted, is also useful in optimizi~g vacuum formation on the forward pump stroke. The blood exiting the pulser loop at the efferent end of the module can either flow up-through the module or out through the filtered blood outlet. The net result is a smaller total flow through the module during the reverse stroke. Thus, th~ aferent end of the module and the forward stroke are the most efficient parts of ~Q the plasmapheresis unit for this mode of operation, and for this reason, it is preferred that the volume of liquid rom the pulser loop be yreater on the forward stroke than on the reverse stroke.
Further regarding the operation of the pul-ser pump on the forward stroke, the liquid requiredto fill the pulser loop can come from three sources:
(1) the filtered blood exit line, (2) the filtered blood just exiting the fibers, and (3) back flow of~
plasma through the fiber pores. The amount provided by each source depends on the relative resistances to flow. During normal operation th ~foresaid back pres-sure valve is closed far enough to maintain a peak transmembrane pressure of 75-130 mm of Hg at the afferent en~ of the module, consequently, back flow from the filtered blood exit line will be minimal.
Ideally, the pulser loop should be filled mostly with filtered blood exiting the fibers, with only a minimum back flow of plasma, to maintain clean pores but not seriously diminish the output of plasma. This desired balance can be achieved in part by adjus~ing the ratio o effective fiber length to lumen diametex (L~D ratio). Usi~g too high an L/D ratio may lead to an undesirable re-duction in the flow of filtered blood from the fibers, thus diminishing plasma production. High L/D ratio~
are also undesirable because the resistance to blood flow is so great that unacceptably high pressures may be necessary to maintain flow; the high pressure may cause hemolysis (see Figure 5 which shows the efect 20 of pore size on allowable transmembrane pressure).
As indicated above, the reversible pulser pump can be adapted to vary any or all of: the frequency of stroke, the length of the stroke, the velocity of the stroke. In a preferred embodiment the pulser :

~6 pump is operated 50 that the volume of liquid passing through the loop on the forward stroke of the pump is greater than the volume of liquid going through the loop on the reverse stroke.
The aforesaid di~cussion presumes that the whole blood inlet and the plasma-depleted blood outlet of ~he module are used as such during the entire plasmapheresis carried out therein. It is to be under-stood, how~ver, that this need not be, since the module can be op~rated in a cyclic fashion such that the functions of the inlet and outlet are periodic~lly reversed.
OE NERAL_DISCUSSION
- The module for carrying out a plasmapheresis in accordance with any of the aforesaid three modes of operation may be described as an improved microfiltra-tion module for separating whole blood into a cellular-enriched fraction and a plasma-enriched fraction, the module comprising in combination a plurality of porous, blood wettable hollow fibers having pores capable of 14 1 ~ri~ ~L~
passing plasma but not cellular components, the fibers being further characterized in ~hat the pore size is within the range 0.1 to 1.0 llm, preferably 0~4 tv 5 0.6 ~m, and the lumen diameter (D) is no more than 0.050 cm, preferably D is 0.015 to 0.050 cm, the fibers being of substantially equal lengths and terminating in first open ends and second open ends; a liquid tight housing to contain the ibers; liquid tight sealing 10 means cooperating with the housing and the first open ends of the fibers; liquid tight sealing means cooper-ating with the housing and the second open ends of the fibers, the two sealing means dividing the housing into two end chambers and one central chamber, the end 15 chambers being in liquid transfer relationship with each other through the hollow fibers; blood inlet means for introducing whole blood into one end chamber;
blood ou~let means for removing a cellular-enriched (plasma-depleted) hlood fraction from the other end chamber; and plasma outlet means for removing a plasma-enriched blood fraction from the central chamber, the improvement characterized in that the effec-tive length (L) of each fiber is not greater than 16,400 cm~l D2, that is, the ~/D ratio is no greater than 16,400 cm 1 D (L and D being in centimeters). "Effective length" is defined as that portion of the fiber, between the ends, through which plasma passes~ Exclud~d from the effective .

~ 5~
1~
length, therefore, are those por~ions of the fibers, at the ends, embedded in the sealing means, for example, a potting resin. It is to be understood regarding the aforesaid ranges of membrane pore size that the porous membrane fibers used herein have pores which are sub-stantially uniform in size and that the substantially uniform size must be within the recited ranges.

At D - 0.033 cm with ~he aforesaid L/D ratio, in carrying out the pulsed flow mode of the invention, it has been found that the use of hollow fibers having an L/D ratio of not greater than about 540, and esp~ci-ally those having an L/D ratio of about 100 to about 350, can provide high plasma flux, that is, rate of plasma collection (Qp), with high outlet hematocrit lS (hct), that i5, volume per~ent of red blood cells in the plasma-depleted blood which is collected. In the - steady state mode of the invention, the L/D ratio should not be greater than about 300, preferably about 100 to about 300. In the recycle mode of the invention, the L/D ratio should not be greater than about 460, prefer-ably about loo to about 350. In general, the lower the L/D ratio within the aforesaid ranges the more satisactory axe the results achieved. The rate of collection of plasma-depleted (exit) blood is referred to hereafter as Qpc High plasma flux is advantageous because it permits carrying out a plasmapheresis with a ~ , .

~L~2 ri~6f`~

small extracorporeal blood volume. ~t is also advantag-eous because it pexmits carrying out such treatment while exposing the blood ko a minimum area of iber membrane and associated apparatus (foreign substances 5 to the blood).
The fibers should be wettable by the blood and are preferably hydrophilic. The walls should be thin since permeability generally increases as wall thickness decreases.
The hollow fibers can be comprised of mater-ials co~monly available for such use, that is, materials which are or can be made biocompatible, permeable and blood wettable. These include, pa~ticu-larly, polymeric ma~erials such as polyesters, poly-15 amides, polycarbonates, polysulfones, methacrylate polym~rs, acrylonitrile polymers, and polypropylene which has been ~uitably treated to achieve the requi-site wettability. Such hollow fibers can be prepared by known techni~ues. These include, for example, the techniques disclosed by Castro, U.S. Patent 4,247,498;
and Gerlach et al., British Specification 2,026,381A.
~ he module, which comprises fibers, potted in a resin, within a housing, can also be prepared by known techniques. The housing, which can be of any co~enient shape, for example, cylindrical, should be made from a blood-compatible material, such as poly(methyl methacrylate). A blood inlet port is 17 ~,25~36L~t~
located near one end o the housing, for conducting whole blood into the hollow fibers, and an outlet port, for collecting plasma-depleted (cellular-enriched) blood, is located near the other end. A third port, a plasma outlet port, is used for collection of plasma which passes through the walls of the fibers.
The module provides high plasma flux and high outlet hematocrit with small extracorporeal blood volume and small iber membrane surface area.
Preferably, the module includes means for conducting the blood through the fibers in recipro-cating pulsatile flow (pulsed flow), as described in my earlier applications and hereinabove. Such means include, for example, a blood circulating loop between an inlet and an outlet, there ~eing an oscillator ~ located on the loop. The inlet and outlet for con-nection to the oscillator can be the same as or dif-ferent than the inlet and outlet used for feedins blood and collecting plasma-depleted blood, respectively.
The use of hollow fibers in this invention provides numerous advantages over the use of flat mem-branes. Some advantages are: the use of hollow fibers provides a large amount of membrane area in a small volume of space; the hollow fibers do not require 25 membrane plasma drainplates; hollow fibers provide an excellent geometric configuration for achieving a uniform 10~ across the membrane; hollow fibers can be produced economically, as can the housing for the fibers; and no restraining clamps or heavy casings are required for hollow fiber housings. Conveniently, the module containing hollow fibers can be purged of air, filled with saline and stored ready-for_use using techniques routinely used with hemodialysis modulesO S-till another advantage of the hollow fiber module of khis inventlon is ~hat it is reusable, at least once, particularly in the pulsed flow mode of operation. For example, the wettable polypropylene fibers used in the examples hereinater were cleaned readily using dilute aqueous sodium hypochlorite.
The pulsed flow mode of the invention is supexior to both steady state and recycle flows be-cause it removes more plasma per unit area o membrane in a shorter period of time. In addition, the unit can operake continuously for a longer time than the other modes. Moreover, using the pulsed 10w system ~0 provides several attrac-tive advantages to both the user and the manufacturer. A small unit with fewer fibers can oukperform the presently available steady state flow units. The user also beneits from shorter treatment time, smaller extracorporeal volume of blood needed, reduced exposure of the blood to foreign surfaces and reduced module coqt.

.18 ~5~

The steady state mode of the invention can be described as an improved method or plasmaphjeresis carried out in a system with a plurality of blood wet-table porous membrane hollow fibers having open inlet 5 ends and open ou~let ends, each fiber having a lumen diameter (D) of no greater than 0.050 cm, pre~erably O.015 to 0.050 cm, the pore size of the porous membrane being within the range 0.1 to l.0 ~m, preferably 0.4 to 0.6 ~m, the lr,;proved method comprisln~:
-~ (a) conducting blood in a forward direction into and through the fibers while mainta ning a mean positive transmembrane pressure difference across the membranes from inlets to outlets of the hollo-w fibers;
(b) collecting plasma-depleted blood from 1. the outlets of the hollow fibers; and (c) collecting plasma which has passed through the pores of the membranes, the effecti~e length of the hollow fibers being such that the L/D ratio is no greater than 16,400 cm 1 D
(L and D belng in centimeter~)~nd the velocity of the blood in step (a~ being such that the shear rate is 50 to 2500 sec~l, preferably 90 to 100 sec~l.
The recycle mode of the invention can be des-cribed as an improved me~hod for plasmapheresis carried 25 out in a ~ystem with a plurality of blood wettable porous membrane hollow fibers having open inlet ends and open outlet ends, each fiber having a lumen diameter (D) o~ no greater than 0.050 cm, preferably 0.~1~ to _ 0.050 cm, the pore size of the porou~ membrane being ~ 5~
within th~ ran~e 0.1 to 1.0 ~m, preferably 0.4 to 0.6 ~m, the improved mPthod comprising:
(a) conducting ~lood in a forward direction into and through the fibers while maintaining a ~ean positive transmembrane pressure difference across the membranes from inlets to outlets of ~he hollow fibers;
(b) conducting blood in an external circuit from a region near the outlets of the fibers to a region near the inlets of the fibers or, alternatively, from a region near the inlets of the fibers to a region near the outlets of the fibers;
~ c) collecting plasma-depleted blood from the outlets of the hollow fibers; and (d) collecting plasma whic~ has passed through the pores of the membranes, the effective iength of the hollow fibers being such that the L~D ratio is no greater than 16,400 cm~l D (L and D being in centimeters) and the velocity of the blood in step (a) being such ~hat the shear rate is 200 to 2~ 2500 sec~l, preferably 2400 to 2500 sec~l.
The pulsed flow mode of ~he invention can be described as an improved method for plasmapheresis carried out in a system with a plurality of blood wet~
table porous membrane hollow fibers having open inlet ends and open outlet ~nds, each fiber having a lumen diameter (D) of no greater than 0.050 cm, preferably Ø015 to 0.050 cm, the pore size of the porous membrane - - being within the range 0.1 to 1.0 ~m (preferred membranes - - have pores which are o~ substantially uniform size ~ . .
.. 20 within the range 0.4 to 0.6 ~m) r the improvement char-acterized in that ~he plasmapheresis can be carried out continuously, the improved method comprising:
(a) conducting blood in a forward direc~ion 5 into and throuyh the fibers ~ile maintaining a mean positive transmembrane pressure difference across the membranes from inlets to outlets of the hollow fibers;
(b) terminating the forward conducting of blood;
(c) conducting blood through the hollow fibers in the reverse direction~
(d) collecting plasma-depleted blood from the outlets of the hollow fibers;
(e) collecting plasma which has passed lS through the pores of the membranes; and (f) repeating in sequence steps (a), (b~
and (c) to collect additional plasma-depleted blood and plasma, the effective length of the hollow fibers bein~ such 2~ th~t the L/D ratio is no greater than 16,400 cm~l D
(L and D being in centimeters) and the velocity of the blood in steps (a~ and (c), except at the beginning and end of each step, being such that the shear rate is 200 to 2500 sec~l, preferably lonn to 1200 sec~l.
In the pulsed flow method, the volume of blood conducted in either of step (a) or step (c) is at least 5~ of the totaL ~olume of blood in the system. Further regarding this mode of the in~ention, it is to be - understood ~hat ~he transmembrane pressure dif~rence :

~ 5~

across the membranes is negative for part of the distance that the blood is conducted across the membranes. In carrying out the pulsed flow mode, the arithmetic product of: (a) the time-average of the transmembrana pressure while it is positive in a portion of the fiber and (b) the time in that portion of the fiber i5 greater than such product when the transmembrane pressure is negative.
The following examples illustrate the process and module of the invention. The module used in each example, unless otherwise noted, comprised blood wetable polypropylene fibers (prepared by known procedures and commercially availablP) having a 330 ~m lumen, a 610 um outer diameter, pores which were 0.5 ~m in diameter, and a porosity of 70% (that is, 70% open areas). The fibers were encased in a tube made of Lucite~
acrylic resin and potted with a polyurethane resin.
The effective length of the fibers, that is, the usable length of the fibers, which is the portion outside the potted regions, is shown in each example.
Steady State Flow (Exam~les 1-4) Example 1 The module used in this example had 90 fibers, an effective length of 6.35 cm and an L/D of 192. Two units of anticoagulated whole blood were combined, adjusted to an hematocrit (hct.) of 3~%
with saline and conducted through the module by a peristaltic pump. Conditions and results are reported in Table 1 wherein Qpc is the rate of exit (plasma-depleted) ~' 1`~

~ 3 blood and Qp is the rate of exit plasma, both in g/min-u~e. Ater about 60 minutes the plasma-depleted blood outlet pressure suddenly dropped to zero. The cause was a block in ~he module inlet caused by an aggre-gation which is believed to have been the result ofthe incompatibility of the two units of blood. The results, however, are consistent with results of other experiments reported herein and, therefore, it is be-lieved that the incompatibility did not materially de-tract from the value of the experiment as a demon-stration of the invention.
Table 1 Plasma ElapsedPressure flux timeQpc Qp (mm ~g) (mL/min/ Outlet 15 (min~(g/min) (g/min) Inlet Outlet cm~) hct 6 7.38 0.78 50 25 0.013 42 7.2~ 0.63 50 30 0.011 41 26 6.97 0.61 50 30 0.010 41 33 3.50 0.~2 115100 0.014 47 43 3.32 0O42 125105 0.007 43
3.52 0.42 110 85 0.007 43 11.88 0.83 100 60 0.014 ~1 There was no visual evidence of hemolysis.
The rate of introduction of whole blood (Qwb) may be obtained in this and in the other examples and in the experiment by combining Qpc and Qp.
ExamE~e 2 The module used in this example had 90 fibers, an effective length of 8.9 cm and an L/D of 270. Two ~--- ~~ -30 units of anticoagulated whole blood were combined, ----.. 23 ~ 5 ~
adjusted ~o an hc~ of 37~, and conducted through the module by a peristaltic pump. Conditions and results are reported in Table 2.

Table 2 Plasma 5 Elapsed Pressure 1ux time Q c Q (mm Hg) (mL/min/ Outlet (min~ (g/~ln) (g/~in) Inlet Outlet cm2? _ hct 7 2.79 0.93 60 45 0.011 49 13 2.63 0.91 65 48 0.011 50 18 10.55 1.32 5S 20 0.016 42 27 10.32 1.~3 55 15 0.015 41 ~6 5.92 1.31 105 75 0.016 45 43 6.22 1.12 105 75 0.014 44 51 5.63 1.2~ 120 95 0.015 45 57 2.6i3 0.83 165 150 0.010 4~
lS 66 2.82 1.01 170 155 0.012 50 77 10.52 1.40 1~0 120 0.017 42 86 10.57 1.11 165 110 0.013 41 There was no visual evidence of hemolysis.
Example 3 The module used in this example had 90 fibers, an effective length of 11.4 cm and an L/D of 346. Two units o anticoagulated whole blood were combined, adjusted to an hct. of 38%, and conducted through the module by a peristaltic pump. Conditions and results are reported in Table 3.

Table 3 Plasma Elapsed Pressure flux time Qpc QP(~n Hg) (rnL~min/ Outlet (min)(~/min) (g/min) Inlet Outlet cm2i hct (%) -6 5 . 30 1. 02235 165 0 . 010 45 11 7 . 32 i. 13235 14Q 0 . 010 44 16 6. 18 0. 98230 140 0 . 009 4 21 5.48 0.8075 25 0.008 44 26 6. 83 0 . 68 80 25 0. 006 . 42 32 6. 68 0 . 72 80 25 0 . 007 42 10 36 6 . 82 0. 8890 30 0. 008 43 42 9 ~ 43 1. 34150 70 0. 012 ~3 49 1~. 71 1. 24150 85 0 . 011 ~2 54 10.70 1.40155 95 0.013 43 63 3.53 0.5$ 150 115 0~005 44 15 67 3. 62 0. 5216~ 120 0. 005 43 Hemolysis was visually observed in plasma collected while the inlet pressure was about 230 mm Hg.
After the pressure was lowered, the plasma cleared and no further hemolysis was observed.
Example 4 The module used in this example had 90 fibers, an effective length of 12. 7 cm and an L/D of 385. One unit of anticoagulated whole blood, adjusted to an hct. of 38~6, was conducted through the module by a 25 peristaltic pump. Conditions and xesults are re-ported in Table 4.

2~ ~5~
Table 4 Plasma Elapsed Pressure ~lux time Qpc Qp (mm Hg)(mL/min/ Outlet (min)_ (g/min) (~min) Inlet Outlet cm2 ~ hct (~) 9 9.10 1.3550 -7 0.011 ~4 14 8.60 1.4587 23 0.012 44 28 9.48 0.9087 21 0.007 42 8.91 1.35110 42 0.011 44 9.80 1.28138 45 0.010 43 ~0 9.23 1.05135 60 0.009 42 10 54 7.05 3.18270 180 0.027 55 58 ~.02 2.82450 335 0.024 56 Hemolysis was visually observed in the last two plasma samples collected, thought to be due to the high pressure to which the blood was subjected. Scan~
ning, by measuring light transmission using conventional procedures, at 650 to 500 nm indicated hemoglobin `, levels of 5~0 mg/dL in the sample taken at 54 min and 37.6 mg/dL in the sample taken a~ 58 min.
Reciprocatory Pulsatile Flow (Examples 5-9) Example_5 The module used in this example had 90 fibers, an effective length of 8.9 cm and an L/D of 270. Two units of anticoagulated whole blood were combined, adjusted to an hct. of 38~, and conducted through the module by a peristaltic pump. To minimi~e membrane fouling, the blood was conducted by reciprocatory pulsatile ~low by means of a peristaltic pump on a . , , . 27 line extending from the inlet to the outlet of the module, in accordance with the techniques disalosed in my earller-f iled applications . Conditions and results are reported in Table 5~ .The pulsed 10w S D.S. number (Duggins-Shaposka number) is derined as the ratio of the shear rate effects to the efects due to the rate at which whole blood is supplied to the unit.
Qwb + Qpulse Pulsed Flow D. S. ~umber = Qwb Qwb = the flow rate of whole blood Qpulse = the flow rate of pulsed blood At steady state conditions, that is, without pulsing, the D~SO number is 1.

28 ~ ~5~6f~
Table S
Pulse Pulse ~lapsed volume frequency time Q ç QP (mL) loscillations) (min)_ (g~ln) (~/min) Forwerd Reverse 8 6.02 1.71 0.04 0.0~ 40 13 6.37 1.52 0.04 0.04 ~0 19 6.74 1.20 0.04 0.04 40 23 2.1~ 1.84 0.14 0.14 ~0 27 3.02 1.78 0.14 0~14 40 2.86 1.68 0.14 0.14 40 37 3.23 2.. 01 0.14 0.14 ~0 44 0.42 0.44 0.30 0.30 4~
0.78 0.68 0.30 0.30 40 58 5.88 2.66 0.22 0.22 40 63 5.62 2.32 0O22 0.22 40 0.68 0.62 0.07 0.07 40 76 0.51 0.51 0.07 0,07 40 83 6.22 1.78 0.11 0.18 ~0 86 6.48 1.61 0.18 0.11 40 6.62 1.40 0.1~ 0.11 70 29 ~5~6~;~
Table S (cont.) Inlet Ou~let Plasrla Elapsed Pres~ure Pressure ~lw~
time (mm Hg) (mm Hg) (mL/min/ Outlet (min) D.S.# Max. Min. Max. Min. cm2) hct (%) 8 1.490 65 55 35 0.020 49 13 1~480 50 45 20 0.018 47 19 1.~70 30 30 10 0.014 45 23 3.995 -30 70 ~45 0.022 71 27 3.4100-40 55 -45 0.021 60 3.5100-40 55 -45 0.020 60 10 .37 3.215010 120 -10 0.024 62 44 29.0110 <-50 25 -50 0.005 78 17.5105 <-50 20 -50 0.008 71 58 3.090 <-50 5 -25 0~032 55 63 3.2120 <-50 5 -30 0.028 54 5.4-80 -25 50 - 5 0.007 73 76 6.675 -30 45 ~ 5 0.006 76 83 2.5150 0 40 -30 0.021 49 86 2.5105-20 75 -15 0.019 47 3.5110-35 110 -50 0.017 ~6 30 1~ 5~
There was no visual evide~ce of hemoly~is.
These results show that improved plasma flux and out-let hct. can be achie~ed by use of rec~procatory pulsa-tile f low.
Example 6 The module used in this example had 9 0 ~ibers, an efective length of 6 . 4 cm and an L/D of 192. Whole blood, having an hct. of 41~ adjusted to 3a~ with saline, was conducted through the module by 10 means of a peristaltic pump. To minimize membrane fouling, the blood was conducted by reciprocatory pul-sa~ile flow, with the inlet and outlet of ~he module being connected by a loop, in accordance with techni~ues disclosed in my earlier-filed applications. Conditions L5 and results are reported in Table 5.

.

Table 6 Pulse Pulse Elapsed volume frequerlcy time Qpc Qp (mL) (oscillations (min)(g/min) (g/mln~Forward Reverse per min) 7 3 . 88 0 . 82 0. 04 0 . 04 40 12 3 . 62 0 . 78 0 . 04 0 . 04 40 16 3 . 69 0 . 7~ 0 . 04 0 . 04 40 23 0.95 1.13 0.18 0.18 40 27 1.09 1~18 0.18 0.18 ~0 32 1.18 1.08 0.18 0.18 40 38 0.74 0.82. 0.18 0.18 40 43 0.68 0.62 0.18 0.18 40 47 0 . 62 0 . 51 0 . 18 0 . 18 40 7.13 1.32. 0.11 0.11 40 6 . 64 1. 45 0 . 11 0 . 11 40 6.79 1.~1 0.11 0.11 40 73 3.16 1.~3 0.26 0.26 40 ~1 3 . 20 2 . 08 0 . 26 0 . 26 40 2. 82 1 . 93 0 . 26 0 . 26 40 6L~

Table _ (cont~ ) Inlet Outlet Elapsed Pressure Pressure Plasma time(~un Hg) (n~n Hg) f lux Out:let (min) D. S ._# Max. Mln. Max . Min . (mL/min/cm~) hct (96) 7 1. 7 90 65 70 50 0 . 014 4~
12 1. 7 85 60 65 45 0 . 013 46 16 1.7 85 60 65 45 ~.013 46 23 7.9 75 -35 65 -50 0.019 83 27 7 . 4 120 -20 110 -40 0 . 020 79 10 32 7 . 4 150 0 125 -25 0 . 0i8 73 38 10. 2 110 -40 9S<-50 0 .014 80 43 12.1 105 -45 90<~50 0.010 73 47 13 .8 115 -45 90<-50 0 . 00~ 69 55 2 . 0 75 5 30 0 0 .02~ 45 ` 15 60 2 . 0 70 10 40 S 0 . 024 46 2.0 75 10 40 5 0.025 46 73 5.1 90 -50 60<-50 0.033 61 81 5. 0 95 -50 65<-50 0 . 035 63 5.4 90 -50 65<~50 0.033 64 .~2 E ample 7 The module used in this example had 90 fibers, an effective length of 3.5 inches (8.9 cm~, an active membrane sur~ace area of 83 cm2, and an L/D
of 269. ~11 tubing in the system was 1/8" (3.2 mm) I.D. and a micrometer valve was used in the blood out-let line ts regulate pressure. One unit (ne~ 524 g) of o positive whole hlood havirlg an hematocrit of 34%
was used. Plasmapheresis was carried ouk for 71 min-utes, at which time the blood supply was exhausted.
During the first 17 minutes the module was operated in the steady state mode; the remainder of the run was carried out using the pulsed 10w mode. The pulsed f low data are shown in Table 7.

Table 7 Pulse Pulse Elap~ed ~olume frequency time Qpç Q (mL) (oscillations (min~ (g/mln) (g/~in) orward Reverse _per min) 521 3.71 1.00 0.3 0.3 10 24 3.85 1.10 0~3 0.3 10 28 3.68 1.33 0.3 0.3 20 32 3.62 1.30 0.3 0.3 20 36 4010 1.24 0.3 0.3 30 1040 4.42 1.00 0.3 0.3 30 .45 3.22 2.29 0.62 0.6230 48 3.86 1.98 0.62 0.6230 53 3.08 1.49 0.62 0.6240 2.~9 1.75 0.46 0.4640 156~ 2.90 1.71 0.46 0.4640 69 3.57 1.74 0.3 0.3 40 ~25~36L~
Tab le 7 ( con t . ) Inlet Outlet ElapsedPressurePressurePlasma time(~Tun Hg)(nur~ Hg) flux Outlet (min~ Max. klin. Max. ~in. (mL/min/cm2) hct (9~) 21 125100 110 75 0 . 012 D~3 24 ïso 60 125 75 0 . 013 44 ~8 150 5~ 125 60 0 . ~16 ~6 32 150 60 135 75 0. 016 46 36 150 50 120 40 0 . 015 4~
115 20 80 15 0. 012 42 135 -15 105 -45 0. 028 58 48 125 -25 95 -5C 0. 024 51 53 105-100 60 -8C 0.018 50 B0 -65 50 -65 0 . 021 55 64 100 -70 45 -65 0. 021 54 ~9 90 -~5 75 -5Q 0. 021 51 36 ~ S ~

The module used in ~his example had 708 fibers, an effective length of 5.625 inches (14.3 cm), an active membrane surface area of 1,050 cm2, and an L/D of 433. The whole blood irllet and plasma outlet lines were 1/8 inch (3.2 mm) I.D. and the plasma-depleted blood and pulser loop lines were 3/1~ inch (4.8 mm) I.D. The pressure was adjusted on the blood outlet line with a hose clamp. Two units (net 537 g and 566 g) of o positive whole blood having a hemato-crit of 39.5~, diluted to 38.5% with sterile saline, were used. Plasmaphere~is was carried out rapidly for 46 minutes at about a 40 ml/min whole blood ~hroughput rate. The supply of blood was depleted in about 15 minutes, after which the plasma-depleted and plasma fractions were combined and rerun through the module.
Recombination of fractions was effected twice during the run. The pulse ~requency was 40 cycles/min. Th data for this run are shown in Table 8; data were col-lected at ~ intervals (1 min each) uniformly spacedthroughout the 46 minute run.

37 ~ 2 Table 8 Pulse vo lume P la sma (~/mln) (~/min) Forward Reverse (mL/lUx/ 2) Outlet 23.77 14.61 1.37 1.27 0.014 62 25.35 11.91 1.37 1.63 0.011 57 25.80 1~ .03 lo 37 1.63 0.011 S5 21.75 15.99 1.37 1.27 0.015 67 27.83 16.43 1.37 1.31 0.016 61 27.22 14.91 1.37 1.31 0.013 60 23. ~1 14.64 1.37 1.31 0.014 63 26.48 11.65 1.31 1.27 0.011 55 38 ~5~

The module used in this example was similar to that used in Example 8, except that the plasma-depleted blood outlet and the plasma outlet were con-5 nected back ~o the whole blood supply so that thesy~tem could be run continuously for almost 4 hours.
Two units (net 540.6 g each) of o positive whole blood having an hematocrit of 40.5% were used and the module and tubing were filled with sterile saline. Plasma-10 pheresis was carrled out for 30 minutes to efectdilution of the whole blood and the saline to an hematocrit of 36%. The pulse frequency was 40 cycles/
min. as in Example 8. Data were collected every 30 minutes during the run and are shown in Table 9.
Table 9 Pulse volume Plasma Qpc QP (mL) flux 2 Outlet (~/min) ~ Forward Reverse (mL/min/cm ? hct (%) 19.87 17.30 1.37 1.27 0.016 67 21.35 15.93 1.37 1.27 0.015 65 20.58 17.06 1.37 1.27 0.016 66 20.79 16.71 1~37 1.27 0.016 65 20.15 17.20 1.37 1.27 0.016 67 21.36 16.04 1.37 1.27 0.015 63 20.8~ 16.97 1.37 1.~7 0.016 65 During the entire run of 230 min, 3850.2 mL of plasma -, was produced at a rate of 16.7 mL/min.

39 ~ 5~

Exam~le 10 This example was carried out to d~monstrate the recycle flow mode of the invention. The module S had 90 fibers, an effective length o~ 3.5 inches (8.9 cm) and an L/D of 269. The whole blood used had an hematocrit of 38~. Conditions and results are re ported in Table lO. In the table, RF indicates that the recycle flow was reversed. Although such reversal thus is outside the embodiment of Figure 2, the results achieved prior and subsequent to the reversal were not adversely af~ected and, mvreover, the results achieved during the reversal were comparable to those achieved with the embodiment of Figure 2. Therefore, it has been concluded that the liquid in the recycle loop can flow in either direction in this mode of the invention `40 i O 1~ Cl~ CO
.
. 1'~ t~7 r-l O r~ 1` ~r el~ G
s ,~
~J-- ~ u~ N U;~
~ O
O ~
-~`3 ~ ~ In ~3 X S 1~l r-l O I O O O O C~ O
rl O O O O O O O O O

_~ ~ ~ I 1 0 0 0 0 0 0 0 0 ~ e a~ u~ O ~, o u~ o o u~ u~ o _~ _I o ~ _I r~ ,I c3 ,I r~
I

~ ~o ~ e~
o o o o o o o ~, o u~
O
~1 H
a~

(~J U ~ l E-~ ~ E~ u~ In Lr~ Ll~ U~ ~
t) 3 ~ . . o . . . . Ln Lr) Ln a) o ~ ~ ~ ~ a~
-:: ~ r~ ~r o u~ ~ o o -~1 ~ O ~ ~ r~
Q~
~ ~I _l o o o o o o o -,~ ~ ~o ~ o ~r ~ a ~D ~1 O ~ 7 0 0 ~ o ~ Cl r~ o ~r ~ ~
-Q' a~~`
~1 ~ r~ o ~ o ~~X) a O ' '- `' ., ~ .
4~ 364~
Example 11 Example 10 was repeated except that th~
fiber effective length was 6 inches (15.2 cm) and the L/D was 462. Conditions and results are ~eported S in Table 11. After 42 minutes the inlet pressure ex-ceeded 350 mm Hg, resulting in severe hemolysis and the Qpc dropped to 0. When the pressure was lowered, plasmapheresis continued satisfactorily.

42 ~L~58~

Cq . `.9 !:~

a)--0~

-E3 X ~: .-1 o o o o o o o tl O O. O O O O O O

C~ C: O O O O O O

' ~ OOO U~ O O O O
O--~ ~l O ~ I O
~ ~: O
O~
,1 u~ e _~
~--~ ~ o~ O o U~ o al ~ _~ a~
_I ~ ~ ~ I
Q ~1 A
E~ a3 _ O ~ t: p~
,1 a~.,l _ tn o 3 ~1 a~ O ~
.,., _ U~
~1 t~ ~ ~ ~ ~ cr o u~
C~ ~ _~ _1 o o o o ~1 o CJ~

C o~ 1 O al ~ ~
1 co~~ ~r o ~3 o r~
-~ .

~ ~_, . ~
, 4 3 1~5~6~
Stead~ State Flow Experiment ~A Comparat ~
The module used in this experiment is
5 presently commercially available. It had ~520 fibers of the same kind used in Examples 1 to 11, an effective length of 24 cm and an L/D of 728. Two units of anti-coagulated whole blood were combined, adjusted to an hct. of 37~, and conducted through the module by a 10 peristaltic pump. ~xit (plasma-depleted) blood and plasma which were collected during the procedure were admixed and returned through the module four times so that the length of the experiment could be extended to ensure steady state conditions. Because the re-15 sults throughout the r~n were consistent, i~ wa~ con-cluded, as in Examples 8 and 9, that the use of recom-bined blood did not materially affect the results o~
this experiment. Conditions and results are reported in Table 12 ~4 ~l~5~
T~ble 12 Plasma Elapsed Pressure flux time Q Q (mm ~Ig) `(mL/min/ outlet (min) (g/~ln) (~in) Inlet Outlet cm2) hct (~) 3 72.7 28.10 135 120 0.00~ 51
6 80.5 28.90 125 110 0.006 50 9 84.2 28.90 13S 120 0.006 50 12 84.7 27.90 150 130 0.006 49 14 79.0 32.60 130 110 0.007 52 1~ 17 8~.7 26.60 170 1~0 0.005 49 19 78~3 28.40 145 115 0.006 50 22 80.8 27.40 15S 125 0.006 49 24 60.2 22.10 175 160 0.004 50 29 59.2 21.30 175 160 ~.004 50 There was no visual evidence of hemoly~is.
Comparison of these results with the results of Examples 1, 2.and 3 reveals that improved plasma flux with sub-stantially equivalent outlet hct w~re achieved using the modules of the invention, which modules had approxi-mately one-fourth to one hal~ of the volume of the module used in this experimen~ for comparison. In order to better compare these results with results attained using the modules of the invention, the re-sults of Examples 1, 2 and 3 were normalized to the conditions of this experiment by use of a regression -- : .equation derived from the above test data. -These cal~
culated results are tabulated in Table 13 to show the predicted outlet hct and plasma f lux using the module~
of the inveIltion at the conditions existing at the time intervals reported in this experiment. Data from Ta}: le 12 are repeated to show ~he actual (measured) re-S sults from the experiment.

, . , ~ .... .

......... ,.. , .. ~
.~ .

46 ~ L.
Table 13 Outlet Hct (~ 2nd Plasm~ Flux ~mL/min/cm2): Predicted for Module Lengths of Examples 1, 2 and 3 and Actual for Module o~ the Experiment 5 Elapsed Predicted Measured Predicted time ~x. I Ex. 2 Ex. 3 ~xp.
(min) (L/D-192) (L/D-270) (L/D=346) (L~D=728) Exp.
3 45 47 49 ~1 52 0.010 0.008 0~007 0,005~.005 0.010 0.009 0.008 0.0050.005 0~010 0.009 0.008 0O0050.005 -~ 0.009 0.008 0.0050.005 0.010 0.003 0.308 0.0060.005 17 4~ 46 47 49 50 0.010 0.008 0.007 0.0050.005 0.~10 0.008 0.007 0.005~.
22 ~4 46 48 50 51 0.010 0.008 0.007 0.0C5U.005 24 45 ~7 49 ~1 52 ~.008 0.007 0.006 0.0040.004 0.008 0.007 0~00~ 0.0040.004 Avg. 45 47 48 50 51 0.010 0.00~ 0.007 0.0050.005 StaØ48 0.52 0.63 0.920.67 ~ev'n, 0.0008 0.0003 0.0002 0.0006 0.0004 It is to be under~tood that although the re-gression equation was calculated based on the actual results o~ Examples 1, 2 and 3, there may be some error in the predicted resul~s~ It is believed, however, that any error is small (see standard deviation).
Using the results of Examples 1 to 4 and other experi ments not reported herein in regression equations, it has been predicted that hollow fiber modules having fibers with luman diameters smaller or larger than 330 ~m are useful and are ~ithin the invention pro- ;
vided the equivalent L/D at 330 ~m is less than about 530, preferably being about 100 to-about 350, in accord-ance with the aforesaid formula for L/D.
U~ing regression analysis to evaluate other plasmapheresis data obtained by means of the instant invention (not included in this specification), Table 14 was assembled to show the expected performance of the hollow fiber module of the invention under steady flow conditions (D.S. number of 1) and under conditions of reciprocatory pulsatile flow (D.S. numbers of 3 to 9~.
Pulsed f low D . S . number (Duggins-Shaposka number) has ; been defined in Example 5. Table 14 thus shows the predicted outlet hct and plasma flux at various length : 20 to diameter (L/D) ratios at various effective fiber lengths at various D. S. numbers. All units from which the data were collected were comprised of blood wet-table polypropylene fibers of 330 ~m lumen diameter, 610 ~m outer diameter and pores of 0.5 ~m diameter.
The through-put was 0.036 mL/minute/fiber at an inlet pressure of 75 ~n of Hg. The inlet hct of the blood was 38%. It may ~e seen from Table 14 that when the L/D
ratio exceeded abou~ 540, the outlet hematocrik and-~

. plasma flux values decreased to less acceptable levels.

. 47 ~ ~ ~ ~ o ,~ W ~ Ln ~ i~ o ~ o U~ O
. o . o o . o ~ o . o . o o o o el~ . Ln . ~ . ~ . ~ . O . CO . Ln ~O ~O ~O ~DO u~O ~0O ~DO LOO Lno r ~P a o ~ r o -n o~ ~ o ~ ~ o ~ ~ D CO
~J ~ ~er ~1~ _Ia~ ,~ ~--I ~ r~l ~ oo c:~
~i . ~ O O ~ O ~ ~ O O O ~ O
~D O ~O O D O ~ O U~ O ~ O ~ O ~D O ~O O

D7 ~ ~ Ln ~ ~ ~ U~ O ~ O ~ ~ O
~1 ~ I . O o . O O o o O . O O
~D L~ l LS~ o . O O . ~ oo I~ ~r .
~ ~ o ~o or~ or` o r` o ~D O ~O O ~ O ~D O
_ ' Z Ln ~ ~ ~1~D ~cr ~o~r ~ _1~ ,~ ~1 ~ o C5~ ~ L~ I O ~1 ~ O
E~. ~: I . o . o . o . o . o . o . o o o U u~ ~ . ~ . o .,1 . ~ . _I . o . ~ . r~ .
. ~O O ~D Or~ or--o ~ o t~ o r~ o ~ o ~ o n~ .1 Q
oP ~ ~1 ~ o ~ ~ ~ ~I Ln ~ O o ,~_ ~ -1 o o ~ . o o o o ~ o o E3 ~ O ~
`_IU u~ o ~D O~1 01` 0 r~ O1~ C~ t' O L
.~23: X
~J ~ ~r ~ o ~ r ~ Ln ~ ~ ~ L~ 0 0 ~` N O ~ r~ ~ O ~L~ r-lN --I O ~ l ~ O
~ ~1 o o o o o o o o o _I ~ . Ln ~0 .L~ . ~ . co . r~ .
'~ O ~D O~O O~D O ~O O ~O O W O ~O O ~ O
~ ~i o ~n (~ Ir) cr~ ~ r~~ Lt~t` ~ N ~ ~ N ~ O O (~
,~ ~ ~ ~ ~ILn _l_1~ ~ ,~ ~ _1 ~ ,J a~
p~ ~rl . o . o . o . o . o . o . o . o o 1-- O . .t~l ~r .Lt~ .LO . U~ ') . Ln Ln O D O ~O O ~ O\~) O~9 O. ~O O W O ~ O
e~ o ~ a~o coo co ~ r Ln ~ O
0 _I N O '1 0~) O N O O 01~-- O ~ O O O

O ~r O ~r O er O Ln O Ln O Ln o Ln o n o ~_ U
,r: ulLn ~ o ~0L~O C~lLn ~PO ~~Ln OO ~Ln LO
~1 .C~; D r~7 ~~ COel~ O~r ~tLtl t~lLn ~ L0 Ln LD
C V
a) c , _ _ _ _ _ _ Q~ 0 L~ l O
t~ s) oel~ o r L

, ~9 s ~3 ~ L~;~

~ o~ - o~ o o ~ o Ln o~r o ~r o ~r ~1 0~` O a~ o o. o . o o .
~ ou~ ou~ o r~ o ~ o ~-- o r Io o. o . o ou oIn o COo ~o ~o o~ o_I o ~ol. o o . o u~ . ~ . a~ .
~_ _. ~o oo o U7 o ~ ~ I~ ~oCO 1`~ ~
o:: ~ ~I o~ o cr~ o U~ ~ nlo o .o _ ~ ~9 .~ . o .
dP ~ U~ O~ O~D O
~r _~
~ ~ ~ o ~o a~ u-- r o1` o ~ o _~ ~: ~ 1 o o o X In ~ ~ .
~~ ~ ~o o~o o~o o E~
o~
~ ~ co o_I oa~ o O ~ ~ I. O O . O
U~ ~ ~ . ~ .
0 W O~D OIn o P~
o~ mu~ ou~
Ln o a: o ~ o --'I O ~ .
u~ o In o u~ o U~ o ~ ~ ~ o ~
cr S r~ a oo o ~:: U ~
,:1 H ~_ _ 1` ~
n In 9 .

so ~ 2 5 ~
It may be seen from the data in Table 14 that, at a given L~D ratio, there is an optimum degree of pulsatility (D.S. number) for achieving a maximum in hematocrit and/or a maximum in flux. One skilled in the art will understand that, in carrying out the plasmapheresis process of this invention, the operator usually selects a compromise between the highest attain-able hematocrit and the highest attainable flux. For example, although the process of the invention can be carried out in such a way that a 90~ hematocri~ can be obtained in the plasma-depleted bloo~, the goal hematocrit usually is no greater than 70%; preferably, it is about 65%. As the goal hematocrit is lowered, the achievable flux is increased. Thus; althouah higher fluxes are achievable by means of the process of this invention, a flux of about 0.04 mL/minute/cm2 represents a desirable compromise since, at this value an hematocrit of 65% is readily achievable. Such an achievable combination of flux and hematocrit repre- -sents a marked advance over art plasmapheresis processes and apparatus, particularly continuous plamapheresis and apparatus.
In addition to the aforesaid correlation be-tween pulsatility, L/D ratio, hematocrit and flux, one ~killed in the art will also recognize that these parameters are dependent on the flow rate of the whole blood flowing through the system. Finally, it is to be Sl ~ ~ 5 ~
understood that all of the examples and the single experiment described herein, except for Examples 7 to 3, were carried ou~ with whole blood adjusted ~o an hct of 37~38~, and that differen~ results (hct and flux) would be obtained at different hematocrit starting levels. In general, when a plasmapheresis is carried out in the art, male blood which has a normal hema-tocrit of about 44-45% is diluted with anticoagulant t~
an hematocrit of about 38~; female blood which has a normal hematocrit of about 38~ is diluted with anti-coagulant to about 30%.
The ollowing discussion is intended to sup-plement the aforesaid disclosure in that it outlines steps which one skilled in the art may follow in carrying ou~ a plasmapheresis by means of the invention.
In addition to definitions already provided, the fol-lowing may be useful:
- 1) Recycle D.S. number = ~

Qwb = the flow rate of whole blood Qrecycle = the flow rate of recycle 2) N = the number of fibers in the module 3) The active ~urface area of the fibers (A) =
~D~L wherein D and L are in cm 4) Shear rate (SeC-l) = 4(flow veloc ty in lumen radius in cm 1. Select a whole blood inlet feed rate Qwb based on treatment ~eeds~

2. Select the whole blood inlet hematocrit based on availability.
3. Select the hematocrit for the outlet cellular-enriched fraction (maximum o 60~ without hemolysis).
4. Calculate the outlet plasma flow Qp from steps 1-3.
5. Select diameter initially at 0.033 cm.
6. From the data given in Tables 14 and 15, select the desired plasma 1ux and outlet hematocrit.
Note length in table and calculate whole blood flow/
fiber from data in table, that is, 70 mL/min feed and 2,000 cm2 surface area.
7. Calculate the whole blood shear rate to compare with data of Table 16.
a. Calculate the number of fibers needed from steps 1 and 6.
9. Calculate the membrane surface area.
10. If desired, select a different lumen diameter.
11. Calculate a new rate of whole blood flow per fiber to get the desired shear rate.
12. Calculate the number of fibers needed.

13. Calculate the fiber length needed to give the same area as before.
14. Calculate L/D to compare with data ~rom above a~d in Table 16.

53 ~5~
Recycle Steady State Flow l~ Follow the steps outl! ined above ~or steady state flow. Ma~imum hçmatocrit is 57-61 with-out hemolysis in accordance with Table 15 and the examples.
2. Select a cellular-enriched blood recycle rate that gives the selected peak shear rate (see Table 16).
3. Select lumen diameter initially at 0.033 cm.
4. Determine plasma flux an~ fiber length from Table 15~ or alternatively from Tables lO or ll.
5. Calculate number of fibers and surface area.
6. Use same procedure design for o~her dia-meters, keeping shear rate and area the same as beforeO
Reciprocatory Pulsa ile Flow l. Select a whole blood inlet feed rate Qwb based on treatment needs.
2. S~l~ct the outlet plasma ~low Qp.
3. Select the whole blood inlet hematocrit based on availability.
4. 5elect the hematocrit for the outlet cellular-enriched fraction based on trea~ment needs and goals.
5. Use an arbitrarily low L/D initially, for example, 100-200.

6. Ass~ne a lumen diameter of 0.033 cm initi-ally.
7. From the data given in Table 17 sel~c~
the highest whole blood flow per fiber to give ~he desired hematocrit for the outlet cellular-enriched fraction at selected L/D.
8. Calculate the whole blood shear rate and adjust the whole blood flow per fiber Qwb to give the desired shear rate.
9. Calculate the number of fibers needed from Qwb and treabment requirement~.
lO. Calculate fiber length from L = L~D x D.
11. C~lculate the membrane surface area rom number, diameter and leng~h of fibers.
12. If desixed, select a different lumen diameter.
13. Calculate a new rate of whole blood flow per fiber to get the selected shear rate.
14. Calculate as before the number of fibers ~eeded.
15. Calculate the fiber length needed to give the same area.
16. Calculate L/D ar.d compare with the data from Table 16.
17~ Select the pul~e frequency;
18. Calculate '~he xequired pulsed blood flow rate and select the pulsed blood volume and time during a 1/2 pulse.

. . .

19. Calculate the total blood flow rate per pulse for the desired peak shear ra~e and resulting D.S. number.
As suggested above, Table 16 includes data which may be used in connection with the aforesaid out-lined steps for carrying out the three modes of opera-tion o. the inventionO

5~
Table 15 Comparison of the ~xpected Performance of Hollow Fibers with Constant Surface Area of 2000 cm2 When Operated in Steady Flow (D.S. Number=l) and Recycle Flow (D.S. Number >1) Modes, All Unit.~ Operating at a Thru-Put of 70 mL/min 5(Total) and an Inlet Pressure of 70 mm of Hq Length ~S - 2 DS = 4 DS = 6 DS = 8 Inches (cm) Steady Recycle ecycle Recycle Recycle L~D
2.5 H= 47.5 -47.7 49.1 50.9 192 (6.4) F=0.007 -0.0070.007 0.008 3.0 ~= 48.2 -47.4 49.4 51~g 231 (7.6) F=0.007 -0.0060.008 o.nog 103.5 H=48.8 - 47.149.9 53.3 269 (8.9) F=0.008 -0.0060.008 0.01 N= 2170 4.0 H= 43.2 - 47 50.5 55 308 (10.2)F-0.008 -0.0060.008 0.01 4.5 H= 49.5 -46.9 51.4 57 346 (11.4)F=0.008 -0.0060.009 0.011 5.0 H= 49.6 43 47 52.4 - 385 (12.7)F=0.0080.0040.006 0.009 15N= 1519 5.5 H= 49.6 42.3 47.1 53.7 - 432 ~14.0)F=0.0080.0030.006 0.01 6.0 H= 49.4 41.6 47.3 55.1 - 462 (15.2)F=0.0080.0030.006 0.01 6.5 H- 49.1 - - - - 500 (16.5)F=0.008 7.0 H= 48.7 - - - 539 20(17.8)F=0.008 7.5 H= 53.9 - - - _ (l9.1)F=0.006 - 3.0 H= 54.2 (20.3)F=0.006 ?~

. S6 57 ~ ~ 5 Table 16 __ Pulsed Flow Minimum Best Mode Maximum Hct in (%) >0 38 90 Hct out (~) >0 65 90 Lumen diameter D (cm) 0.015 0.033 0.OSQ
Inlet feed pressure 10 75-130 250 (mm Hg)at 0.5 ~m pore diameter Plasma flux (mL/min/cm2) >0 0.042 - -Whole blood shear rate 100 198 1200 ( sec~l) Pulsed blood peak shear lO0 948 2500 rate (sec~l) Peak shear rate (sec 1) 200 1146 2500 Pulse frequency (cycles/ 20 40 80 .
min) Pulsa volume/1/2 pulse - 1.2 1.4 cycle (mI ) Duration of pulse/1/2 - oO 75 pulse cycle ( sec) at 40 cycles/min Pulse pressure (mm Hg) - -20 Length of ibers (cm) at >0 6.6 11.4 0.5 ~m pore diameter L/D at D - 0O033 cm - 200 540 Membrane surface area - 1174 ( cm2 ) Inlet flow rate Qwb lO 72 400 (mL/min) 25 Whole blood flow rate/ - 0.042 f iber (mL/min) Peak flow rate/fiber - 0.244 . (m~/min) , 58 ~ 5~L~
Ta~le 16 (cont.) Minimum est Mode Maximum No. of fibers - 1713 Plasma flow rate Qp - 30 (mL/min) Blood outlet pressure - -20 (mm ~g) Steady State Flow Hct in (~) >0 38 ~ct out (%) >0 49 60 Lumen diameter D (cm) 0.0150.033 0.050 Whole blood shear rate - 94 2500 (sec-l) Length of fibers (cm) - 6.3 8.9 Inlet feed pressure - 75 250 (mm ~g) at 0.5 ~m pore diameter L/D at D = 0.033 cm - 192 300 No. o fibers - 3469 -M~mbrane surface area - 2285 (cm2) 20 Inlet blood flow ra~e Qwb - 72 (mL/min) Flow rate/fiber (mL/min) - 0.021 : Plasma flow rate Qp - 16 (mL/min) Plasma flux (mL/min/cm2) - 0.007 - .
Minimum blood outlet - 50 <250 pressure (mm Hg) at 0.5 ~m por~ diameter _cycle Steady_State Flow , .. . .. . .
Hct in (%) - 38 Hct out (~) - 55 57-61 ~8 59 31..~5B6 Table 16 (cont. ) Minimum Best Mode Maximum Lumen diameter D (cm) 0.015 0.033 0.050 ~nlet feed pressure - 70 250 (mm Hg) Total blood flow shear - 2450 2500 rate (sec 1~
Inlet blood flow rate - 65 Qwb (mL/min) P~ecycle blood flow rate - 388 (mL/min) Plasma flow rate Qp _ 20 (mL/min) No. of fibers _1688 Plasma flux (mL/min/cm2) - 0.01 15 Membrane surface area - 2000 (cm2) Length of i~ers (cm) - 11.4 L/D at D = 0.033 cm . - 345 460 Flow rate/fiber minimum ~ 0.268 6~ 6~

ol co o ~1 ~ ~ a ~ u~ O O u~ o ~ o ~o o o l cn o ~ ~ GO o ~ ~ o u~ o ~ ..... ~ ..........
v~ r-r''.DIn ~ ~ ~ N_I OO a~ a~ t~

o ¦ ~~ ~ r~~o O N~r ~ O~ D O ~r a~ ~) r~
O
~0 ~~ 0 5~ o u~

o ¦ ~~ ~ ~~ ~~n D ~ O N11 O
h 117 a~0~ r`~011 ~ ~~1 r I --I O a~ 00 I~
R

q . ~. ~ . . . ~ ~ .
3 ~ 5p .-1 o a~ co ~` ~D In er ~ ~ ~ .-1 o cn ~ c~ r`
:~, 3 Q O ~Y7 ~ ~1 ,t O O --~ ,1 ~ ~ ~ ~ ~ c~ ~ Ln O t~ ~
_I ~ ~ ~ ~ ~ ,( o ~n oo t~ ~D U~ ~r ~ ~ ~ ,~ o ~ ~o a~
a) ~ o ~ ~ o ~ ~ oo co co a~ o ~1 ~ ~ r~
~:2 Ul ~ r~ UJ ~ ~ ~ N O C~ Q~ ~ ~ ~ N --1 o a~
E~ ~ ~ co co 0 co r~ o w ~1 Cl ~ O ~ ~ 0 OD CO C~ O ~1 ~ ~ U~ C~
5~ O ................
r~ . ~ ~ r~ O co 1~ ~O u~ ~r ~ ~ ~ ~ o G~ CO
~ . ~ A
¦ ~J 0 ~D Ln ~ ~ N r l ~1 ~I r~ l 0 ~ Ir) r--O
_I o a~ c~ 1~ Ln ~ ~ ~ ~ o a~ a~ r~ ~D In ol _I ~1 ~ ~O ~ ~1 ~ 0~ ~O L~ ~ ~ ~ ~ ~ ~ U~
~1 ~ I O a~ o u~

,4 ~
o ~ ~ o ~ o ~ ~ ~ o ~
u~ OOOOOOOOoOOOOOOOO
~1 ~
C)OOOOC~OOOoo~oOooo 5 ~ ~f j L~ ~

O ....................
r~ ~ ~ ~ ~ o o o o ~ cn ~ ~ a~

o IS'~ ~1 1` ~ o r~ ~ ~ 0 C~ C) O O r-l ~n .

o ~ a3 ~ ~ u~ In ~ o co ~o ~ ~ ~ o o ~ a~ a~
O ..................

In . . . . . . . . . . . . .
m ~ ~ ~ --I --I o o o ~ c~ 0 ~
~D ~ ~ ~O ~O ~ ~D ~O U7 Lr U~ Lt~ U~ Ln ~ In u~ n Ln o I ~o o ul o u~ ,1 ~o ~ ~ r) ~ ~ r~ er ~ ,1 a~ c~ r~
o . . . . . . .. .
u~ ~n ut ~ ~ ~ ~ ~ ~ ~ _l ~ o o o o o ~ a~
~ ~ O ~ ~ W In u ~r~ Ln r~ N ~ O U~ O 1~ 0 ~ 0 11'1 ~ 0 0 ~` ~ Cr ~r ~ o o o ~

r ~ ~o Ln Ln ~ ~ r~ ~ ~ ~ ~ ~1 ~ ~1 _~ ~ o o r~ U') ................ ~ .. , _~ ~ co r~ I o o o ~ o _I
O O ~ ~ o o ~ cs ~r ~ el~ O ~D ~ ~ ~n ~ ~ t--~ O ........ .. . .. ......
E~ ~ ~ t` ~ ~o o ~ cr~ ~ co o l a~ ,1 ~ ~ ~ ~ ~D o ~ ~ ~ ~ r o co In ........ .... .....

o ~;3~03 C3 ~03 ~C3 ~r ~.3 U'3 U3 U'.3 U') m ~.3 L~ m ~ Ç3 O ~13 t- a~3 ~3 r.3 Ir.3 a3 ~ 4r CC3 ~ r 0 U3 0 U`.3 0 ~53 ~ 1;~3 _3 t~''3 _3 C3 0 a~3 0~ t~ r~ ~C3 U'.3 U`.3 ~ ~53 ~.3 ~3 t~l, C~3 3~ 3 ~ O
~C3~r ~3 ~ 3 Lt`.3 In In IS`.3 U3 Ir~ Ir,3 3Si3 Ir.3 U U'.3 11'.3 Ln3 U-3 U~ Lr3 .~3 .,~" eS'3 ~C3 ~ri3 0 ~ ~t3 ~3 i3 0 ~L3 ~3 U 3 ClCi3 0 ~. "$3 ~J CC3 0 t~
3 ~3 e ~ ~3 ~t3 Ll`i3 U'l U'.3 U'~ Ln 1.~ ~ 3 ~ C3 ~ ~ i3 CIC3 O ~ O O O O O O O O O O O O O O C3 0 0 0 0 0 ~ ~ 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 O O O C3 Pl3-' ~62 3L;;~5 o~ o ~ ~ o ~r o . . ~ . . . . . .
r~ ~ a~ o o o o ol ~ ~ ~ ~D ~ ~ ~ ~D
~r o l o ~1 ~ ~ ~ ~ a~
o o ¦ ~ ~ N ~'1 ~r In 1` ~ --1 u~

o o ~ CS C~ ~ o o l ~7 r~ ~
er O O O O O O O O O

~ ~o r o o o o o c: o o o O
u O
l~ Ln . . . . . . .
_~ r~ ~ ~ cl~ ~ ~ ~ a~
a) "~ L~ 1~ L'~ ILn ~1 Itl L'l 111 o u~ ~ ~1 o ~ c~
~ O
E~ ~ ~ c~ co oo r~ ~ 1-- 1~ 1--O Ul ~ O ~ r-- D L'~
1~1 L'l If l 11'1 U~ L') L'l L'~
o C~ t~ L'~ ~ ~1 O
L'~ U-) Itl Ltl L~

Lr o o c~ ~ a~ ~ OD ~ C~

rl ~ ~ O ~ ~P ~ CO O
~ ~ ~ ~ c~ ~ o O ~ O O O O O O C:~ O
_l, 1 1 1 ~a~E3 ooooooooo p~ _ 6;~

~3 Bes~ Mode 1~5~6L~
The best mode presently ontemplated fvr carrying out each of the three modes of the invention is summarized in Table 16.
Preferred embodiments of the invention are illustrated by the above descriptions and examples.
However, the invention is not limited to the precise constructions herein disclosed but, ra~her, includes all modifications and changes coming within the scope of the following claims.

15.

~5

Claims (31)

1. Improved microfiltration module for separating whole blood into a cellular-enriched fraction and a plasma-enriched fraction, the module comprising in combination a plurality of blood wettable porous membrane hollow fibers having pores of substan-tially uniform size and capable of passing plasma but not cellular components, the fibers being further character-ized in that the pore size is within the range 0.1 to 1.0 µm and the lumen diameter (D) is no greater than 0.050 cm, the fibers being of substantially equal lengths and terminating in first open ends and second open ends;
a liquid tight housing to contain the fibers; liquid tight sealing means cooperating with the housing and the first open ends of the fibers; liquid tight sealing means cooperating with the housing and the second open ends of the fibers, the two sealing means dividing the housing into two end chambers and one central chamber, the end chambers being in liquid transfer re-lationship with each other through the hollow fibers;
blood inlet means for introducing whole blood into one end chamber; blood outlet means for removing a cellular-enriched blood fraction from the other end chamber;
and plasma outlet means for removing a plasma-enriched blood fraction from the central chamber, the improve-ment characterized in that the effective length (L) to lumen diameter (D) ratio (L/D) is not greater than 16,400 cm-1 D.(L and D being in centimeters).
Z. Module of Claim 1 wherein the L/D ratio is not greater than about 540.
3. Module of Claim 1 wherein the L/D ratio is about 100 to about 350.
4. Module of Claim 3 wherein the pore size is within the range 0.4 to 0.6 µm and the lumen diameter is 0.015 to 0.050 cm.
5. Module of Claim 1 wherein the fibers are blood wettable polypropylene fibers.
6. Module of Claim 1 wherein the fibers are purged of air and filled with saline.
7. Module of Claim 1 further comprising means for conducting blood through the fibers in reciprocatory pulsatile flow.
8. Module or Claim 7 wherein the means for conducting blood through the fibers in reciprocatory pulsatile flow comprises a blood circulating loop be-tween an inlet and an outlet, there being an oscillator located on the loop.
9. Improved method for plasmapheresis car-ried out in a system with a plurality of blood wettable porous membrane hollow fibers having a substantially uniform membrane pore size and having open inlet ends and open outlet ends, each fiber having a lumen diameter (D) of no greater than 0.050 cm, the pore size of the porous membrane being within the range 0.1 to 1.0 µm, the improved method comprising:

(a) conducting blood in a forward direction into and through the fibers while maintaining a mean positive transmembrane pressure difference across the membranes from inlets to outlets of the hollow fibers;
(b) collecting plasma-depleted blood from the outlets of the hollow fibers; and (c) collecting plasma which has passed through the pores of the membranes, the effective length of the hollow fibers being such that the L/D ratio is no greater than 16,400 cm-1 D (L and D being in contimeters) and the velocity of the blood in step (a) being such that the shear rate is 50 to 2500 sec-1.
10. Method of Claim 9 wherein the lumen diameter (D) is 0.015 to 0.050 cm and the pore size of the porous membrane is within the range 0.4 to 0.6 µm.
11. Method of Claim 10 wherein the shear rate is 90 to 100 sec-1.
12. Method of Claim 10 wherein the L/D ratio is not greater than about 300.
13. Method of Claim 10 wherein the L/D ratio is about 100 to about 300.
14. Method of Claim 9 wherein the fibers are blood wettable polypropylene fibers.
15. Method of Claim 9 comprising:
(a) conducting blood in a forward direction into and through the fibers while maintaining a mean positive transmembrane pressure difference across the membranes from inlets to outlets of the hollow fibers;
(b) conducting blood in an external cir-cuit from a region near the inlets or outlets of the fibers to a region near, respectively, the outlets or inlets of the fibers;
(c) collecting plasma-depleted blood from the outlets of the hollow fibers; and (d) collecting plasma which has passed through the pores of the membranes, the effective length of the hollow fibers being such that the L/D ratio is no greater than 16,400 cm 1 D (L and D being in centimeters) and the velocity of the blood in step (a) being such that the shear rate is 200 to 2500 sec-1.
16. Method of Claim 15 wherein the lumen diameter (D) is 0.015 to 0.05 cm and the pore size of the porous membrane is within the range 0.4 to 0.6 µm.
17. Method of Claim 16 wherein the shear rate is 2400 to 2500 sec-1
18. Method of Claim 16 wherein the L/D ratio is not greater than about 460.
19. Method of Claim 16 wherein the L/D ratio is about 100 to about 350.
20. Method of Claim 15 wherein the fibers are blood wettable polypropylene fibers.
21. Method of Claim 9 comprising:
(a) conducting blood in a forward direc-tion into and through the fibers while maintaining a mean positive transmembrane pressure difference across the membranes from inlets to outlets of the hollow fibers;
(b) terminating the forward conducting of blood;
(c) conducting blood through the hollow fibers in the reverse direction;
(d) collecting plasma-depleted blood from the outlets ot the hollow fibers;
(e) collecting plasma which has passed through the pores of the membranes; and (f) repeating in sequence steps (a), (b) and (c) to collect additional plasma-depleted blood and plasma, the effective length of the hollow fibers being such that the L/D ratio is no greater than 16,400 cm-1 D
(L and D being in centimeters) and the velocity of the blood in steps (a) and (c), except at the beginning and end of each step, being such that the shear rate is 200 to 2500 sec-1.
22. Method of Claim 21 wherein the lumen diameter (D) is 0.015 to 0.050 cm and the pore size of the porous membrane is within the range 0.4 to 0.6 µm.
23. Method of Claim 22 wherein the shear rate is 1000 to 1200 sec-1.
24. Method of Claim 22 wherein the L/D ratio is not greater than about 540.
25. Method of Claim 22 wherein the L/D ratio is about 100 to about 350.
26. Method of Claim 21 wherein the fibers are blood wettable polypropylene fibers.
27. Method of Claim 21 wherein the volume of blood conducted in step (a) is different from the volume of blood conducted in step (c).
28. Method of Claim 27 wherein the volume of blood conducted in step (a) is greater than the volume of blood conducted in step (c).
29. Method of Claim 21 wherein the volume of blood conducted in either step (a) or step (c) is at least 5% of the total volume of blood in the system.
30. Method of Claim 21 wherein the trans-membrane pressure difference across part of the mem-branes is negative for part of the distance that the blood is conducted across the membranes.
31. Method of Claim 30 wherein the arith-metric product of: (a) the time-average of the trans-membrane pressure while it is positive in a portion of the fiber and (b) the time in that portion of the fiber is greater than such product when the transmem-brane pressure is negative.
CA000443383A 1982-12-16 1983-12-15 Hollow fiber plasmapheresis module and process Expired CA1258642A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US450,221 1982-12-16
US06/450,221 US4668399A (en) 1982-02-16 1982-12-16 Hollow fiber plasmapheresis process

Publications (1)

Publication Number Publication Date
CA1258642A true CA1258642A (en) 1989-08-22

Family

ID=23787248

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000443383A Expired CA1258642A (en) 1982-12-16 1983-12-15 Hollow fiber plasmapheresis module and process

Country Status (15)

Country Link
US (1) US4668399A (en)
EP (1) EP0112173B1 (en)
JP (1) JPS59120162A (en)
AT (1) ATE45502T1 (en)
AU (1) AU570019B2 (en)
BR (1) BR8306936A (en)
CA (1) CA1258642A (en)
DE (1) DE3380399D1 (en)
DK (1) DK580083A (en)
ES (2) ES528027A0 (en)
GR (1) GR78782B (en)
IE (1) IE55079B1 (en)
IL (1) IL70456A (en)
MX (1) MX157826A (en)
ZA (1) ZA839291B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3672898D1 (en) * 1985-05-27 1990-08-30 Asahi Medical Co HYDROPHILE POROESE COMPOSITE MEMBRANE, METHOD FOR THEIR PRODUCTION AND A PLASMA SEPARATOR.
ES2041668T3 (en) * 1986-10-29 1993-12-01 Asahi Medical Co., Ltd. UNIT OF COLLECTION OF COMPONENTS OF THE BLOOD.
US4950224A (en) * 1988-08-05 1990-08-21 Healthdyne, Inc. Apparatus and method for in vivo plasma separation
CA1325175C (en) * 1989-05-25 1993-12-14 Asahi Medical Co., Ltd. Compact plasma separator and an apparatus containing the same
US5017293A (en) * 1989-08-24 1991-05-21 Pfizer Hospital Products Group, Inc. Multi-pass blood washing and plasma removal device and method
DK119490D0 (en) * 1990-05-14 1990-05-14 Unes As Apparatus for the preparation of a concentrate of coagulation factors, such as the fibrinogen, from a blood portion
US5234608A (en) * 1990-12-11 1993-08-10 Baxter International Inc. Systems and methods for processing cellular rich suspensions
DK167517B1 (en) * 1991-11-11 1993-11-15 Squibb & Sons Inc CONTAINER FOR INCLUSION AND SEPARATION OF A FLUID, PRETTY BLOOD PLASMA, IN ITS INGREDIENTS
US5554293A (en) * 1993-06-28 1996-09-10 C. R. Bard, Inc. Disposable blood washing and apheresis device and method of using thereof
ZA948564B (en) * 1993-11-19 1995-07-26 Bristol Myers Squibb Co Liquid separation apparatus and method
US5733446A (en) * 1994-12-02 1998-03-31 Bristol-Myers Squibb Company Centrifuge with annular filter
CN1174515A (en) * 1994-12-02 1998-02-25 布里斯托尔-迈尔斯斯奎布公司 Centrifuge reagent delivery system
WO1996016714A1 (en) * 1994-12-02 1996-06-06 Bristol-Myers Squibb Company Method and device for separating fibrin monomer from blood plasma
EP1109564B1 (en) * 1998-08-31 2006-02-22 Julian L. Ambrus Method for removal of hiv and other viruses from blood
US7291122B2 (en) * 2000-03-24 2007-11-06 Immunocept, L.L.C. Hemofiltration methods for treatment of diseases in a mammal
ES2198216B1 (en) * 2002-07-02 2005-04-16 Juan Carlos Instituto Cientifico Y Tecnologico De Navarra, S.A.(67%). MEANS OF CULTURE OF MOTHER-PROGENITORS CELLS HUMAN AND ITS APPLICATIONS.
AU2003255276A1 (en) * 2002-08-13 2004-02-25 Arbios Systems, Inc. Selective plasma exchange therapy
CN101124315A (en) 2003-01-17 2008-02-13 伊势龙医学股份有限公司 Method for removal of viruses from blood by lectin affinity hemodialysis
US8142844B2 (en) 2003-09-17 2012-03-27 Gambro Lundia Ab Separating material
US7740804B2 (en) * 2005-04-12 2010-06-22 Chromedx Inc. Spectroscopic sample holder
CA2507323A1 (en) * 2005-05-13 2006-11-13 Chromedx Inc. Diagnostic whole blood and plasma apparatus
CA2517299A1 (en) * 2005-08-26 2007-02-26 Chromedx Inc. Hollow needle assembly
US20100245803A1 (en) * 2005-04-12 2010-09-30 Chromedx Inc. Blood sample holder for spectroscopic analysis
US8206650B2 (en) * 2005-04-12 2012-06-26 Chromedx Inc. Joint-diagnostic spectroscopic and biosensor meter
US7384549B2 (en) * 2005-12-29 2008-06-10 Spf Innovations, Llc Method and apparatus for the filtration of biological solutions
US8747669B1 (en) 2005-12-29 2014-06-10 Spf Innovations, Llc Method and apparatus for the filtration of biological samples
WO2012002263A1 (en) * 2010-06-28 2012-01-05 協和機電工業株式会社 Hollow fiber forward osmosis membrane
WO2015006515A1 (en) 2013-07-09 2015-01-15 Sri International Biomarker panel for dose assessment of radiation injury and micro plasma filter
CA3088023C (en) 2018-03-08 2023-03-21 Repligen Corporation Tangential flow depth filtration systems and methods of filtration using same
KR20230079245A (en) 2018-05-25 2023-06-05 리플리겐 코포레이션 Tangential flow filtration systems and methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3342729A (en) * 1964-12-09 1967-09-19 Dow Chemical Co Permeability separatory cell and apparatus and method of using the same
GB1381410A (en) * 1971-12-10 1975-01-22 Kroyer K K K Process of diluting or concentrating a solution by osmosis dialysis or ultra-filtration and apparatus for carrying out said process
GB1442754A (en) * 1972-06-28 1976-07-14 Nat Res Dev Apparatus for and method of effecting heat or mass transfer berween fluids
US3853756A (en) * 1973-02-12 1974-12-10 Westinghouse Electric Corp Reverse pressure cleaning of supported semipermeable membranes
CH582013A5 (en) * 1974-09-17 1976-11-30 Univ Bern Pathophysiologisches
US4247498A (en) * 1976-08-30 1981-01-27 Akzona Incorporated Methods for making microporous products
US4191182A (en) * 1977-09-23 1980-03-04 Hemotherapy Inc. Method and apparatus for continuous plasmaphersis
JPS55500370A (en) * 1978-05-25 1980-06-26
JPS559227A (en) * 1978-06-30 1980-01-23 Fujitsu Ltd Character display system using gas discharge panel
JPS56110625A (en) * 1980-02-05 1981-09-01 Takeda Chem Ind Ltd Separating method of blood plasma and apparatus for the same
US4381775A (en) * 1980-02-05 1983-05-03 Takeda Chemical Industries, Ltd. Method for low pressure filtration of plasma from blood
US4343705A (en) * 1980-10-31 1982-08-10 Instrumentation Laboratory Biological liquid fractionation using alternate opposite flow directions across a membrane
DE3279765D1 (en) * 1981-07-22 1989-07-20 Du Pont Plasmapheresis by reciprocatory pulsatile filtration

Also Published As

Publication number Publication date
AU570019B2 (en) 1988-03-03
IL70456A (en) 1988-02-29
BR8306936A (en) 1984-07-24
ES8600946A1 (en) 1985-11-01
JPS59120162A (en) 1984-07-11
US4668399A (en) 1987-05-26
ATE45502T1 (en) 1989-09-15
EP0112173B1 (en) 1989-08-16
ES539188A0 (en) 1986-04-01
ES528027A0 (en) 1985-11-01
MX157826A (en) 1988-12-15
ZA839291B (en) 1985-07-31
EP0112173A2 (en) 1984-06-27
DE3380399D1 (en) 1989-09-21
EP0112173A3 (en) 1986-02-26
IL70456A0 (en) 1984-03-30
DK580083A (en) 1984-06-17
IE832954L (en) 1984-06-16
AU2244983A (en) 1984-06-21
DK580083D0 (en) 1983-12-15
ES8605689A1 (en) 1986-04-01
IE55079B1 (en) 1990-05-23
GR78782B (en) 1984-10-02

Similar Documents

Publication Publication Date Title
CA1258642A (en) Hollow fiber plasmapheresis module and process
US4735726A (en) Plasmapheresis by reciprocatory pulsatile filtration
US4729829A (en) Hollow fiber plasmapheresis module
US4936980A (en) Apparatus and method for plasma separation
US5242384A (en) Blood pumping and processing system
EP0038203B1 (en) Blood treatment apparatus
US20030236482A1 (en) Apparatus and method for in-vivo plasmapheresis using periodic backflush
IT1320024B1 (en) METHOD FOR ADJUSTING THE INFUSION IN A DIALYSIS MACHINE AND DIALYSIS MACHINE FOR THE APPLICATION OF THE MENTIONED METHOD.
EP0432897B1 (en) Blood pumping and processing system
EP0076665B1 (en) Method and apparatus for plasmapheresis
US5017293A (en) Multi-pass blood washing and plasma removal device and method
Najarian et al. Enhanced microfiltration of bovine blood using a tubular membrane with a screw-threaded insert and oscillatory flow
EP0070738B1 (en) Plasmapheresis by reciprocatory pulsatile filtration
US4753733A (en) Plasmapheresis method and apparatus for overcoming membrane fouling
EP0112094B1 (en) Apparatus for blood treatment
US4565626A (en) Apparatus for blood treatment by pressing blood into treating material and then drawing it out
US11911549B2 (en) Plasmapheresis device
CA1269620A (en) Plasmapheresis by reciprocatory pulsatile filtration
WO1995002443A1 (en) Device and method for processing biological fluid
Nosé et al. Plasma filtration detoxification on hepatic patients: its optimal operating conditions
Lysaght et al. Mass transfer in arteriovenous hemofiltration
Jaffrin Blood cross flow filtration through artificial membranes
JP2023154449A (en) Body cavity fluid treatment device and concentrator
FR2563443A1 (en) Process and device for separating substances in solution or in suspension by ultrafiltration, application to plasmapheresis
CA1197472A (en) Plasmapheresis filtration module

Legal Events

Date Code Title Description
MKEX Expiry